ClinicalTrials.Veeva

Menu

Pregnancy and Medically Assisted Conception in Rare Diseases (EGR2)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Myositis
Mastocytosis
Antiphospholipid Syndrome
Sjogren Syndrome
Various Autoimmune and/or Systemic and/or Rare Diseases
Scleroderma
Spondyloarthritis
Vasculitis
Psoriatic Arthritis
Systemic Lupus Erythematosus
Rheumatoid Arthritis

Study type

Observational

Funder types

Other

Identifiers

NCT02450396
13.381bis

Details and patient eligibility

About

Rare diseases frequently affect women of childbearing age. Pregnancy in these women has become less rare, but remains associated with high levels of complications. One obstacle to their optimal management during pregnancy is that there are no prospective studies of pregnancy during rare diseases and several connective tissue diseases. As a consequence, the management of these pregnancies is non-standardised in terms of treatment, monitoring (frequency of consultations, laboratory tests and ultrasound), and organisation of care.

Moreover, although these women (all diseases combined) are frequently exposed to medications potentially incompatible with pregnancy, little is known about the frequency of these exposures and especially their consequences to mother and child.

For these reasons, researchers and clinicians from different specialties created an interdisciplinary research group on pregnancy and rare diseases (GR2), intended to improve the management of these patients' pregnancies. Using a single computer server, the investigators plan to set up a large prospective study of pregnancies in patients with rare diseases: various forms of myositis, lupus, antiphospholipid syndrome, Sjogren syndrome, scleroderma, and inflammatory rheumatic diseases. The investigators objective is to analyse the complications of pregnancies in women with rare diseases and then to improve their management and their quality of life.

Enrollment

5,000 estimated patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Woman with a rare and/or systemic disease
  • Pregnancy confirmed by a positive beta-HCG assay or an obstetric ultrasound OR medically assisted conception procedure
  • Patient agreed to participate

Exclusion criteria

  • Adults under guardianship
  • People hospitalised without their consent and not protected by the law
  • Persons deprived of their liberty

Trial contacts and locations

1

Loading...

Central trial contact

Nathalie Costedoat-Chalumeau, PhD; Adèle Bellino

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems